Boston Scientific (BSX) Cash from Investing Activities (2009 - 2026)

Boston Scientific has reported Cash from Investing Activities for 18 years, with the latest figure at -$2.0 billion in Q2 2026.

• Cash from Investing Activities for Q2 2026 came in at -$2.0 billion, down 73.71% year-over-year; the trailing twelve-month figure through Jun 2026 was -$3.6 billion (up 47.3% YoY), and the FY2025 annual result was -$2.6 billion, up 53.58% from the prior year.
• Cash from Investing Activities declined to -$2.0 billion in Q2 2026, from -$591.0 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at -$29.0 million in Q2 2022 and troughed at -$3.7 billion in Q4 2024.
• A 5-year average of -$858.8 million and a median of -$507.0 million in 2025 frame the typical range for Cash from Investing Activities.
• The widest annual swing landed in 2023, when Cash from Investing Activities sank 2796.55%; it then surged 86.18% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at -$183.0 million in 2022, then tumbled by 475.41% to -$1.1 billion in 2023, then slumped by 251.76% to -$3.7 billion in 2024, then surged by 86.18% to -$512.0 million in 2025, then tumbled by 282.03% to -$2.0 billion in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$2.0 billion in Q2 2026, -$591.0 million in Q1 2026, and -$512.0 million in Q4 2025.